PMCB News and Press, PharmaCyte Biotech Inc. From 07/11/22

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS PR Newswire NEW YORK , July 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Fri...

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS PR Newswire NEW YORK , July 5, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the larges...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced the results of a study to determine...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today issued the following statement in re...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its Chief Executive O...

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS PR Newswire Believes the Company's Recently Announced Initiatives are a Reactionary and Transparent Attempt to Placate Stockholders by Conveniently Implementing a Few of Iroquois' Long-Sta...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today issued the following letter to its ...

PharmaCyte Biotech (NASDAQ:PMCB), a nano-cap biotech focused on cellular therapies said on Thursday that its board of directors authorized a share repurchase program to buy back up to $10M worth shares of the company’s outstanding common stock. The program takes effect immediately for ...

PharmaCyte Biotech (NASDAQ:PMCB) has announced a stock buyback plan to repurchase up to $10M of its outstanding common stock over a two-year period. The repurchases will be funded with available cash. Shares of the biotechnology company has surged ~6% pre-market For further details see...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its Board of Director...